Navigation Links
Bivalirudin, a new anti-clotting drug may be a safer option for treatment of acute coronary conditions

A novel anti-clotting drug named bivalirudin is turning out to be a better option than combination drug therapy for patients suffering heightened //coronary conditions, for instance heart attacks.

Lead researcher Dr. Gregg W. Stone, a professor of medicine and director of cardiovascular research and education at Columbia University said, "We use it at Columbia in the vast majority of cases. We find that compared to heparin, it is just as effective and safely allows us to do angioplasty with a major reduction in bleeding episodes."

During a study involving 14,000 patients, who had suffered heart attack or other acute coronary syndromes, study participants were administered either a treatment including heparin, or a package including bivalirudin or just bivalirudin.It was found that Bivalrudin reduced the occurrence of artery blockage or severe bleeding by nearly 14 percent compared to the effects of a drug package that included Heparin.

"It makes care of patients in the cath lab much simpler and safer. The big difference was the reduction of major bleeding, almost 50 percent. Major bleeding has been associated with higher mortality, so it is important for the outcome", Dr. Gregg W. Stone said.

Dr. John A. Bittl, an interventional cardiologist at the Munroe Regional Medical Center in Ocala, commented, "This report states that bivalirudin can be used for patents with acute coronary syndrome with a lower risk of bleeding than conventional treatment."
'"/>




Page: 1

Related medicine news :

1. Enduring anti-clotting treatment avails heart patients
2. Useful device makes spinal surgery safer
3. Transporter offers reliable clues for safer pain medicine
4. Arthritis drugs safer than previously declared
5. Diet and exercise can be a better option to control diabetes
6. Early detection of alcohol abuse is better option for treatment
7. Children obesity has an option in the form of surgery
8. Substituting soymilk for lactose intolerant students n schools: a great option
9. To cope better with HRT, a good option is Hysterectomies
10. Sweet nothings: A fruitful option to assuage the sweet tooth
11. NICE supports application of advanced biological therapies as treatment option for acute psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/20/2017)... Boca Raton, FL (PRWEB) , ... January 20, 2017 , ... ... supplement development, announced it attended the January ECRM trade show to continue the marketing ... technologically advanced vitamin C supplement, known for providing 400 percent better absorption than traditional ...
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, ... everyday lives, recently attended the January ECRM Trade Show in Hilton Head, SC, ... for its large range of supplements that keep the body functioning at its ...
(Date:1/20/2017)... , ... January 20, 2017 , ... "TransFlare 4K Mystique ... inside of Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... Dragon. Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light leak transitions have ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a heartwarming and earnest ... for each of his children. “The Angel” is the creation of published author, Marjorie ... York City, and impassioned writer. , When asked of her new book, Marjorie says, ...
(Date:1/20/2017)... NC (PRWEB) , ... January 20, 2017 , ... ... vPEP ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in a ... by Doug Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive Expiratory ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 Many patients ... for their medication when a pharmacy just a few ... prescription.  To alleviate this problem Medicationdiscountcard.com has ... to see exactly how much their medication will cost ... Made Easy Medicationdiscountcard.com ...
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA ... drugs market is expected to grow at a CAGR of ... of 38.7% in the second half of the forecast period. The ... 2016 to 2027. The market is estimated at $1,058 million in ... ...
(Date:1/19/2017)... 2017 Accuray Incorporated (Nasdaq: ARAY ... continue to set the bar for excellence in customer ... user satisfaction rating among radiation treatment delivery systems in ... Market Intelligence Briefing™. The most recent ratings trend also ... industry peers for 11 of the past 12 quarters. ...
Breaking Medicine Technology: